Biocryst Pharmaceuticals (BCRX) Research & Development (2010 - 2026)
Biocryst Pharmaceuticals' (BCRX) quarterly Research & Development came in at $60.3 million in Q1 2026, up 61.84% YoY from $37.3 million in Q1 2025, and up 47.6% on a QoQ basis from $40.9 million in Q4 2025.
Biocryst Pharmaceuticals (BCRX) Research & Development (2010 - 2026) Analysis & Trends
Biocryst Pharmaceuticals (BCRX) has 17 years of Research & Development data on file, last reported at $60.3 million in Q1 2026.
- Quarterly Research & Development rose 61.84% year-over-year to $60.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $189.2 million (up 14.36% YoY) and the FY2025 annual result came in at $166.1 million, down 4.87% from the prior year.
- Research & Development rose to $60.3 million in Q1 2026, from $40.9 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $73.2 million in Q4 2022 to a low of $37.3 million in Q1 2025.
- A 5-year average of $51.2 million and a median of $48.4 million in 2023 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2024 — Research & Development dropped 29.42% — and 2026, when it surged 61.84%.
- Tracing BCRX's Research & Development over 5 years: stood at $73.2 million in 2022, then slipped by 4.31% to $70.1 million in 2023, then fell by 29.42% to $49.4 million in 2024, then decreased by 17.34% to $40.9 million in 2025, then surged by 47.6% to $60.3 million in 2026.
- The last three Research & Development figures came in at $60.3 million (Q1 2026), $40.9 million (Q4 2025), and $44.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 970.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -1.05 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 146.30 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 248.30 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 326.70 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 92.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Biocryst Pharmaceuticals | 2.46 Bn | 2.11 Bn | 214.41 Mn | 51.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 51.97 Mn |
| Mar 31, 2026 | 60.32 Mn |
| Dec 31, 2025 | 40.87 Mn |
| Sep 30, 2025 | 44.60 Mn |
| Jun 30, 2025 | 43.39 Mn |
| Mar 31, 2025 | 37.27 Mn |
| Dec 31, 2024 | 49.44 Mn |
| Sep 30, 2024 | 41.08 Mn |
| Jun 30, 2024 | 37.62 Mn |
| Mar 31, 2024 | 46.49 Mn |
| Dec 31, 2023 | 70.05 Mn |
| Sep 30, 2023 | 46.88 Mn |
| Jun 30, 2023 | 51.25 Mn |
| Mar 31, 2023 | 48.39 Mn |
| Dec 31, 2022 | 73.21 Mn |
| Sep 30, 2022 | 52.74 Mn |
| Jun 30, 2022 | 61.99 Mn |
| Mar 31, 2022 | 65.36 Mn |
| Dec 31, 2021 | 63.53 Mn |
| Sep 30, 2021 | 49.97 Mn |